| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5602162 (Pediatric) | ORGANON | Imidazole, triazole and tetrazole derivatives |
Jul, 2012
(11 years ago) | |
|
US5298520 (Pediatric) | ORGANON | Triazole containing indole derivatives |
Dec, 2012
(11 years ago) | |
| US5457895 | ORGANON | Method of identifying freeze-dried dosage forms |
Oct, 2013
(10 years ago) | |
|
US5457895 (Pediatric) | ORGANON | Method of identifying freeze-dried dosage forms |
Apr, 2014
(10 years ago) | |
Maxalt-Mlt is owned by Organon.
Maxalt-Mlt contains Rizatriptan Benzoate.
Maxalt-Mlt has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Maxalt-Mlt are:
- US5602162*PED
- US5298520*PED
- US5457895
- US5457895*PED
Maxalt-Mlt was authorised for market use on 29 June, 1998.
Maxalt-Mlt is available in tablet, orally disintegrating;oral dosage forms.
The generics of Maxalt-Mlt are possible to be released after 16 June, 2015.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
| New Patient Population(NPP) | Dec 16, 2014 |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 29 June, 1998
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
How can I launch a generic of MAXALT-MLT before it's drug patent expiration?
More Information on Dosage
MAXALT-MLT family patents
